Key result
Simvastatin treatment in patients with heterozygous familial hypercholesterolemia significantly decreased extrinsic pathway inhibitor activity from a median of 153% to 111% (p<0.001).
Why the study?
Does simvastatin with or without omega-3 fatty acids alter blood coagulation and fibrinolysis parameters in patients with heterozygous familial hypercholesterolemia?
Population
18 otherwise-healthy individuals with heterozygous familial hypercholesterolemia
Design
Cohort
Follow-up
18-20 weeks
Authors
Loading...
May link statin therapy to altered coagulation in HeFH; leaves open clinical thrombotic impact and needs RCT confirmation.
Does simvastatin with or without omega-3 fatty acids alter blood coagulation and fibrinolysis parameters in patients with heterozygous familial hypercholesterolemia?
Absolute Event Rate: 111% vs 153%
p-value: p=<0.001
Simvastatin treatment in hypercholesterolemic patients significantly reduces extrinsic pathway inhibitor (EPI) activity, which correlates closely with reductions in LDL cholesterol.
Sandset et al. (1991) studied heterozygous familial hypercholesterolemia (n=18). Simvastatin followed by omega-3 fatty acids was evaluated on Extrinsic pathway inhibitor (EPI) activity (p=<0.001). Simvastatin treatment in patients with heterozygous familial hypercholesterolemia significantly decreased extrinsic pathway inhibitor activity from a median of 153% to 111% (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: